PSC Biotech Partnered to Expand Automated Plate Reading
The firm will market FDA-cleared AI culture plate technology across North America and Singapore to reach new manufacturing segments.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you trust that outsourcing quality testing to third-party firms improves pharmaceutical manufacturing safety?
Clever Culture Systems has appointed PSC Biotech as its sales agent for the APAS Independence platform in the US, Canada, and Singapore. The FDA-cleared system automates culture plate reading in laboratory workflows.
Why it matters
This partnership aims to accelerate the adoption of automated plate reading among regional and mid-tier pharmaceutical manufacturers. It serves as a tactical expansion to capture markets beyond the company's existing large-pharma client base.
The APAS Independence platform utilizes AI-driven imaging to perform automated culture plate reading. PSC Biotech will install a demonstrator unit at its facility in Pennsylvania to facilitate technical validation for prospective clients.
The players
Clever Culture Systems
A developer of AI-powered diagnostic hardware for pharmaceutical laboratory automation.
PSC Biotech
A life sciences consultancy and service firm supporting over 1,000 customers with regulatory and technical infrastructure.
The details
The APAS Independence platform functions as an automated imaging system designed to analyze culture plates—petri dishes containing a growth medium used to cultivate microorganisms. By using machine learning algorithms to interpret plate images, the system identifies microbial growth without manual inspection. PSC Biotech acts as the lead generation interface, while Clever Culture Systems retains the authority to set final pricing and finalize all sales contracts.
Timeline
October 14, 2026: The partnership agreement was formally announced.
Next 12 months: The partners expect an increase in qualified sales opportunities.
36 months: The initial duration of the sales agent agreement.
FY28 and beyond: Instrument sales resulting from these partnerships are projected to convert.
The Tech Race
This move marks a shift in how automated microbiology platforms compete for mid-market share against legacy manual processes. It parallels the scaling strategies seen in the broader lab automation sector to broaden reach beyond the largest global pharmaceutical manufacturers.
Pharmaceutical manufacturing labs in North America and Singapore will gain local access to demonstration units for the APAS Independence platform. Interested labs can now coordinate technology evaluations through regional PSC Biotech representatives.
The takeaway
The move signifies a transition into a broader market phase for AI-based diagnostic automation in manufacturing. Stakeholders should track the conversion rate of these new leads in fiscal year 2028 to gauge the effectiveness of the third-party sales model.
Further reading
Explore more developments in the field of diagnostic innovation on our Biotech section page.
Live Poll
Do you trust that outsourcing quality testing to third-party firms improves pharmaceutical manufacturing safety?
